What it is
PT-141, or bremelanotide, acts on melanocortin receptors, a family of receptors involved in sexual function, skin color and appetite. It's approved as Vyleesi for women before menopause with hypoactive sexual desire disorder that began after a time of normal desire and happens whatever the situation, partner or kind of stimulation. The label describes it as low sexual desire that causes marked distress or difficulty in relationships, and that isn't caused by another medical or mental-health condition, by problems in the relationship, or by a medicine or drug. Its label calls it a melanocortin receptor agonist, a drug that switches those receptors on, and says how it works for this condition in women isn't known. Sildenafil (Viagra) is a different drug, which its own label calls a PDE5 inhibitor (it blocks an enzyme called phosphodiesterase-5).
What makes it distinct
The label gives one fixed dose, taken as needed: 1.75 mg injected under the skin at least 45 minutes before expected sexual activity, and no more than one dose in 24 hours. It doesn't recommend more than eight doses a month, and few people in its phase 3 trials took more. In 2020 the FDA told a compounding firm (one that mixes drugs from their ingredients) that drug products it had made using bremelanotide weren't eligible for the exemptions that federal law (section 503A) gives some compounded drugs. FDA inspectors had found those products in 2018, before Vyleesi was approved in 2019. One of the FDA's reasons was that bremelanotide wasn't then part of an FDA-approved drug.
Doses on the label
1.75 mg is the only dose the FDA label recommends, and the range here is that dose alone. The label recommends no smaller amount.
Source FDA label for Vyleesi. Checked 28 Oct 2026.
This describes the source. It isn't advice.
Open questions
- What it does outside its approved use. The label says it isn't approved for low desire after menopause or in men, or for improving sexual performance.
- Its label reports studies that gave it through the nose. The approved product is injected under the skin.
Worth knowing
Its label includes safety information, including short-lived effects on blood pressure. It says people with uncontrolled high blood pressure or known heart or blood-vessel disease shouldn't use it. It also says more frequent doses raise the risk of dark patches (focal hyperpigmentation), including on the face, gums and breasts.
More in Melanocortin peptides